Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,654 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05269485RecruitingPhase 1/Phase 2
Hypofractionated radiation for stage III lung cancer
This trial studies a radiation treatment schedule called “hypofractionated radiotherapy” for people with locally advanced (stage III) non-small cell lung cancer who cannot have surgery. It aims to see whether this radiation approach works well and is tolerable for your cancer stage.
Hefei, AnhuiAges 18–70 - NCT05363319Recruiting
Cemiplimab study in adults with advanced lung cancer
This observational study looks at how well cemiplimab works and how safe it is for adults with advanced non-small cell lung cancer in everyday care in Europe. It mainly follows patients already prescribed cemiplimab, and asks them to complete questionnaires.
Klagenfurt, CarinthiaAges 18 years+ - NCT05468242RecruitingPhase 2
Tislelizumab after lung cancer chemotherapy and radiation
This Phase 2 study tests tislelizumab (an immune medicine) given after chemotherapy and radiation for stage III non-small cell lung cancer that has not been treated before. It may help improve how well the cancer responds and how long patients can stay in remission, with or without an added medication called bevacizumab.
GuangzhouAges 18–75 - NCT05751018RecruitingPhase 2
Pyrotinib for first treatment of HER2-mutated lung cancer
This Phase 2 trial studies pyrotinib as a first (initial) anti-cancer treatment for advanced lung cancer that has specific HER2 changes. It aims to shrink tumors and control the cancer, especially in people whose test results show HER2 insertion mutation, point mutation, or amplification.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05922345RecruitingPhase 3
Study drug vs docetaxel for advanced lung cancer after prior treatment
This Phase 3 trial compares AL2846 pills plus TQB2450 injections against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer. You may qualify if your cancer has progressed after platinum chemotherapy and immunotherapy, and if certain tumor genetic tests are negative.
Hefei, AnhuiAges 18–75 - NCT06205927RecruitingPhase 2
Carbon Ion Boost for Advanced Lung Cancer
This trial tests a new way to give radiation therapy (carbon ion boost) to people with advanced, inoperable lung cancer. The goal is to see if targeting the most aggressive parts of the tumor with a higher dose can improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06222489RecruitingPhase 2
HER3 PET scan for advanced EGFR-mutant lung cancer
This study uses a special PET/CT scan to measure a protein called HER3 in your tumors. The scan uses a radioactive version of the drug patritumab deruxtecan (HER3-DXd). This test may help doctors understand how much HER3 is in your cancer and decide if HER3-targeted therapy could work for you.
Amsterdam, North HollandAges 18 years+ - NCT06467500RecruitingPhase 2
Cadonilimab plus chemo for lung cancer after immunotherapy
This trial tests a new drug called cadonilimab combined with chemotherapy for people with advanced lung cancer who have already tried and failed immunotherapy. It aims to see if this combination can help when standard immunotherapy no longer works.
YichangAges 18–75 - NCT06604689Recruiting
AI-guided brain radiation for EGFR-mutant lung cancer with brain mets
This study uses AI to help doctors decide the best way to use brain radiation for people with EGFR-mutant lung cancer that has spread to the brain. It aims to improve treatment planning and outcomes for those already taking a third-generation targeted therapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06623136RecruitingPhase 2
Testing a new combo for advanced lung cancer
This trial tests a new drug (ES102) combined with an immunotherapy (Toripalimab) for people with advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help those whose tumors have high PD-L1 levels.
Beijing, Beijing MunicipalityAges 18–75 - NCT06731907RecruitingPhase 2
Keytruda with or without chemo for advanced lung cancer
This trial tests a new combination of drugs (Keytruda with or without chemotherapy) to see if it works better for advanced lung cancer. It's for people who haven't had immunotherapy or chemotherapy for their cancer that has spread.
Lexington, KentuckyAges 18 years+ - NCT06903377RecruitingPhase 1/Phase 2
ZG005 plus Gecacitinib for advanced lung cancer
This trial tests a new combination of two drugs, ZG005 and Gecacitinib, for people with advanced non-small cell lung cancer that cannot be treated with surgery or radiation. The goal is to see if the combination can shrink or slow the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06908993RecruitingPhase 3
Tepotinib vs standard care for MET-mutated lung cancer
This trial tests a targeted pill called tepotinib against standard treatments for advanced lung cancer with a specific MET gene change. It is for people whose cancer has progressed after at least one prior therapy.
BesançonAges 18 years+ - NCT06928389RecruitingPhase 3
Ivonescimab plus docetaxel for advanced lung cancer
This trial tests a new drug called ivonescimab combined with a chemotherapy drug (docetaxel) for advanced non-small cell lung cancer. It's for people who have already tried platinum-based chemo and a PD-1/PD-L1 inhibitor, and who have not had docetaxel before.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06934343Recruiting
Personalized therapy for advanced lung cancer using data
This trial uses real-world data to study how to personalize treatment for advanced non-small cell lung cancer. It looks at medical records from 2011 to 2024 to find the best therapy approaches.
Salt Lake City, UtahAges Any age - NCT07086456RecruitingPhase 2
Combination therapy for advanced lung cancer
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (surufatinib and tislelizumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this approach works better than standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT07150663RecruitingPhase 3
Megestrol acetate with chemoradiation for stage III lung cancer
This study tests whether a special form of megestrol acetate (a medicine used to help with weight and appetite) can improve outcomes when given alongside standard chemotherapy and radiation for people with stage III non-small cell lung cancer. It is for patients who are not overweight and who are not already using other appetite-boosting medications.
Wuhan, HubeiAges 18–85 - NCT07198841RecruitingPhase 2
Studying IBI351 plus Cetuximab beta for a type of lung cancer
This trial tests a combination of two targeted drugs, IBI351 and Cetuximab beta, for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and hasn't been treated yet. The goal is to see if this combination can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT07668037Recruiting
Understanding long-term survival in NSCLC immunotherapy
This study looks at patients with advanced non-small cell lung cancer who received immunotherapy (immune checkpoint inhibitors) alone or in combination with other treatments. It aims to understand why some patients survive longer than others by analyzing their medical data and using AI to predict outcomes.
BeijingAges 18 years+ - NCT07221474RecruitingPhase 2
Study of a personalized vaccine plus chemo for lung cancer
This trial tests an experimental personalized cancer vaccine (V940) combined with pembrolizumab and chemotherapy for people with advanced squamous non-small cell lung cancer that has spread. The goal is to see if adding the vaccine helps the immune system fight the cancer better.
Tampa, FloridaAges 18 years+ - NCT05430009RecruitingPhase 1
Radiation to liver plus immunotherapy for metastatic lung cancer
This Phase 1 study tests whether targeted radiation to liver tumors combined with immunotherapy can control metastatic non-small cell lung cancer. It aims to find a safe and effective treatment approach for people whose cancer has spread to the liver.
Ann Arbor, MichiganAges 18 years+ - NCT05985330Recruiting
Study of FeNO as a marker for immunotherapy response in lung cancer
This trial is testing whether a simple breath test (FeNO) can predict how well immunotherapy works in people with advanced lung cancer who haven't had treatment before. It's for patients whose tumors have high PD-L1 levels and who will receive immunotherapy alone.
DijonAges 18 years+ - NCT06422143RecruitingPhase 3
Keytruda with or without Sac-TMT for advanced squamous lung cancer
This trial tests the combination of pembrolizumab (Keytruda) with or without a new drug, sacituzumab tirumotecan (Sac-TMT), as initial treatment for advanced squamous non-small cell lung cancer. It aims to see if adding Sac-TMT after initial treatment helps keep cancer under control longer.
Little Rock, ArkansasAges 18 years+ - NCT04999761RecruitingPhase 1
Study testing new drug combinations for advanced cancers
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
AichiAges 18 years+
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,654 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.